Management of HIV-Exposed Infants

  • Wei Li A. Koay
  • Allison L. AgwuEmail author


The majority of new human immunodeficiency virus (HIV) infections in children are acquired perinatally, thus emphasizing the importance of effective management of this vulnerable group of infants born to mothers with HIV. Dramatic declines in new childhood HIV infections since 1995 are largely attributable to global efforts to prevent mother-to-child transmission. These efforts include HIV testing, providing antiretroviral treatment (ART) to pregnant and breastfeeding women living with HIV, antiretroviral (ARV) prophylaxis to infants born to mothers with HIV, intrapartum zidovudine when maternal viral load is not suppressed, and cesarean delivery. The recommendations for diagnosis, treatment, and prevention of HIV infection among pregnant women and their infants are constantly evolving, and the most current recommendations can always be found at


Acquired immune deficiency syndrome Human immunodeficiency virus Infant Nevirapine Prophylaxis Zidovudine 


  1. 1.
    World Health Organization. Global health observatory data. Available at Accessed 13 Feb 2018.
  2. 2.
    Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Centers for Disease Control and Prevention. Enhanced perinatal surveillance—15 areas, 2005–2008. HIV Surveillance Supplemental Report.Google Scholar
  4. 4.
    Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014;28:1049–57.CrossRefPubMedGoogle Scholar
  5. 5.
    Humphrey JH, Marinda E, Mutasa K, et al. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. BMJ. 2010;341:c6580.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bunders MJ, van der Loos CM, Klarenbeek PL, et al. Memory CD4(+)CCR5(+) T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. Blood. 2012;120:4383–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. Am J Epidemiol. 1995;142:1330–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Lewis SH, Reynolds-Kohler C, Fox HE, et al. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. Lancet. 1990;335:565–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Nielsen K, Bryson YJ. Diagnosis of HIV infection in children. Pediatr Clin N Am. 2000;47:39–63.CrossRefGoogle Scholar
  10. 10.
    International Perinatal HIVG, Andiman W, Bryson Y, de Martino M, et al. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340:977–87.CrossRefGoogle Scholar
  11. 11.
    Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341:385–93.CrossRefPubMedGoogle Scholar
  12. 12.
    Marinda ET, Moulton LH, Humphrey JH, et al. In utero and intra-partum HIV-1 transmission and acute HIV-1 infection during pregnancy: using the BED capture enzyme-immunoassay as a surrogate marker for acute infection. Int J Epidemiol. 2011;40:945–54.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012;366:2368–79.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal—infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS. 2000;14:263–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Bollen LJ, Whitehead SJ, Mock PA, et al. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? AIDS. 2008;22:1169–76.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Garcia-Tejedor A, Perales A, Maiques V. Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet. 2003;82:17–23.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    U.S. Department of Health and Human Services. AIDSinfo—Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. Accessed 13 Feb 2018.
  18. 18.
    Lepage P, Hitimana DG. Natural history and clinical presentation of HIV-1 infection in children. AIDS. 1991;5:S117–25.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Caldwell MB, Oxtoby MJ, Simonds RJ, Rogers MF. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Reccomm Rep. 1994;43:1–10.Google Scholar
  20. 20.
    Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS. 1995;9:F7–11.CrossRefPubMedGoogle Scholar
  21. 21.
    Read JS, Committee on Pediatric AIDS. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics. 2007;120:e1547–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–44.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    U.S. Department of Health and Human Services. AIDSinfo—Guidelines for the use of antiretroviral agents in pediatric HIV infection. Accessed 14 Feb 2018.
  24. 24.
    Donnelly M, Davies JK. Contemporary management of human immunodeficiency virus in pregnancy. Obstet Gynecol Clin N Am. 2014;41:547–71.CrossRefGoogle Scholar
  25. 25.
    Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14:415–21.CrossRefPubMedGoogle Scholar
  26. 26.
    Kennedy CE, Yeh PT, Pandey S, Betran AP, Narasimhan M. Elective cesarean section for women living with HIV: a systematic review of risks and benefits. AIDS. 2017;31:1579–91.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Rowland BL, Vermillion ST, Soper DE. Scheduled cesarean delivery and the prevention of human immunodeficiency virus transmission: a survey of practicing obstetricians. Am J Obstet Gynecol. 2001;185:327–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369:1828–35.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rainwater-Lovett K, Luzuriaga K, Persaud D. Very early combination antiretroviral therapy in infants: prospects for cure. Curr Opin HIV AIDS. 2015;10:4–11.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    U.S. Department of Health and Human Services. AIDSinfo—Guidelines for the prevention and treatment of opportunistic infections in hIV-exposed and HIV-infected children. Accessed 14 Feb 2018.
  31. 31.
    Gaur AH, Dominguez KL, Kalish ML, Rivera-Hernandez D, Donohoe M, Brooks JT, et al. Practice of feeding premasticated food to infants: a potential risk factor for HIV transmission. Pediatrics. 2009;124(2):658–66.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of PediatricsJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations